Wall Street Zen upgraded shares of Henry Schein (NASDAQ:HSIC – Free Report) from a hold rating to a buy rating in a report issued on Saturday morning.
Several other brokerages also recently issued reports on HSIC. Morgan Stanley reissued an “underweight” rating and set a $64.00 price target (up from $61.00) on shares of Henry Schein in a report on Friday, April 24th. Citigroup assumed coverage on shares of Henry Schein in a report on Wednesday, April 15th. They issued a “buy” rating and a $100.00 price objective on the stock. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research report on Wednesday, May 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Finally, BMO Capital Markets began coverage on shares of Henry Schein in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $85.00 target price for the company. Eight analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Henry Schein presently has a consensus rating of “Hold” and a consensus target price of $89.36.
Get Our Latest Stock Report on Henry Schein
Henry Schein Trading Up 0.9%
Henry Schein (NASDAQ:HSIC – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The firm had revenue of $3.37 billion during the quarter, compared to the consensus estimate of $3.34 billion. During the same period in the prior year, the business earned $1.15 EPS. The firm’s revenue was up 6.3% on a year-over-year basis. Equities research analysts predict that Henry Schein will post 5.32 EPS for the current year.
Insider Activity
In other Henry Schein news, Director William K. Daniel purchased 10,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the purchase, the director owned 20,000 shares in the company, valued at $1,383,800. This trade represents a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.89% of the company’s stock.
Institutional Investors Weigh In On Henry Schein
Several institutional investors have recently bought and sold shares of HSIC. Invesco Ltd. grew its position in Henry Schein by 4.1% in the 3rd quarter. Invesco Ltd. now owns 4,731,698 shares of the company’s stock valued at $314,043,000 after buying an additional 184,763 shares in the last quarter. Southpoint Capital Advisors LP lifted its stake in shares of Henry Schein by 28.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 3,200,000 shares of the company’s stock worth $235,840,000 after acquiring an additional 700,000 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Henry Schein by 2.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,873,004 shares of the company’s stock worth $211,734,000 after acquiring an additional 56,687 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Henry Schein by 11.3% in the third quarter. Ameriprise Financial Inc. now owns 2,523,014 shares of the company’s stock valued at $167,453,000 after acquiring an additional 256,156 shares in the last quarter. Finally, Bank of Montreal Can boosted its holdings in shares of Henry Schein by 3,655.7% in the fourth quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after acquiring an additional 2,087,666 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Recommended Stories
- Five stocks we like better than Henry Schein
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.
